Physician profile
Camille Andy
NPI 1669420469
$3,662.92
in general payments reported to CMS, 2019-2025
35 companies · $837 in 2025
The $837 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $394 · 2021: $258 · 2022: $171 · 2023: $494 · 2024: $765 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,095.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,043.83 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $454.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $438.32 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $172.65 | 2022-2025 | Eterna, Freestyle Libre 3, Proclaim |
| Amgen INC. | $137.77 | 2019-2025 | Evenity, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $136.33 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.80 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.66 | 2019-2023 | Trintellix |
| Pfizer INC. | $105.02 | 2020-2025 | |
| Astellas Pharma US INC | $89.68 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.75 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $67.03 | 2019-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Dynavax Technologies Corporation | $43.03 | 2024 | Heplisav-B |
| Corium, LLC | $41.80 | 2023-2024 | Azstarys, Adlarity |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $40.16 | 2022-2025 | Vest Therapy Und |
| Exact Sciences Corporation | $39.35 | 2025 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $39.05 | 2025 | Simponi Aria, Tremfya, Stelara |
| Axsome Therapeutics, INC. | $36.90 | 2025 | Symbravo |
| Glaxosmithkline, LLC. | $36.79 | 2019-2023 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $33.56 | 2024-2025 | |
| Abbvie INC. | $30.70 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $29.75 | 2024 | Rexulti |
| Adlon Therapeutics L.P. | $23.81 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $23.76 | 2024 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $22.29 | 2025 | Inspire |
| Boston Scientific Corporation | $20.34 | 2023 | |
| Gilead Sciences, INC. | $17.13 | 2025 | |
| Shield Therapeutics INC | $16.12 | 2025 | |
| Irhythm Technologies, INC. | $15.95 | 2024 | Zio Monitor, Zio Xt Patch |
| Antares Pharma, INC. | $15.81 | 2019 | |
| Valeritas, INC. | $14.25 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.07 | 2024 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $13.92 | 2019 | |
| Amarin Pharma, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camille Andy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.